在转移性乳腺癌中准低HER2:一个不断变化的治疗范式
Charlie Yang1, Christine Brezden-Masley2, Anil Abraham Joy3
1Tom Baker Cancer Centre, University of Calgary, 1331 29 Street NW, Calgary, AB T2N 4N2, Canada.
Therapeutic advances in medical oncology
|June 16, 2023
概括
特拉斯图祖马布德鲁克斯泰干 (T-DXd) 对HER2低转移性乳腺癌患者显示显著的生存益处. 这一发现重新分类和重塑了此前无法治疗的患者群体的治疗策略.
科学领域:
- 在瘤学瘤学.
- 癌症的医学治疗 癌症的医学治疗
- 药理学 药理学是指药理学的学科.
背景情况:
- 从历史上看,转移性乳腺癌 (MBC) 治疗的重点是 HER2 阳性或 HER2 阴性状态.
- 以前,低HER2表达被认为是MBC中不可治疗的生物标志物.
- 在DESTINY-Breast04试验中,研究了这种患者亚组的新型治疗方法.
研究的目的:
- 评估T-DXd在HER2低转移性乳腺癌患者中的疗效.
- 评估T-DXd对激素受体阳性和激素受体阴性MBC的生存结果的影响.
- 讨论这些发现对HER2-低MBC的分类和治疗范式的影响.
主要方法:
- 第三阶段临床试验设计.
- 招募先前接受治疗的HER2-低不可切除或转移性乳腺癌患者.
- 施用trastuzumab deruxtecan (T-DXd) 和对结果的评估.
主要成果:
- 特拉斯图祖马布德鲁克斯泰干 (T-DXd) 在患有低HER2转移性乳腺癌的患者中显示出显著的生存益处.
- 在荷尔蒙受体阳性和荷尔蒙受体阴性子组中观察到这种益处.
- 这表明HER2-低乳腺癌中以前未被识别的目标人群.
结论:
- 特拉斯图祖马布德鲁克斯泰干 (T-DXd) 代表了治疗低HER2转移性乳腺癌的重大进展.
- DESTINY-Breast04试验结果需要重新评估作为治疗目标的HER2表达.
- 需要进行进一步的研究,以解决管理这种患者群体的挑战和证据差距.
关键词:
在HER2-低的水平下.针对HER2的向疗法化学疗法 化疗 化疗转移性乳腺癌 转移性乳腺癌萨基图祖马布 (Sacituzumab) govitecan可以使用.特拉斯图祖马布可以脱.治疗顺序的顺序处理.更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.8K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.7K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
01:30Cancer Vaccines
434
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
434